<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260779</url>
  </required_header>
  <id_info>
    <org_study_id>PV-10-EA-02</org_study_id>
    <nct_id>NCT01260779</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors</brief_title>
  <official_title>Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provectus Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provectus Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This compassionate use protocol provides expanded access for investigational use of PV-10 in&#xD;
      cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is&#xD;
      no comparable or satisfactory approved alternative therapy and whom, in the opinion of the&#xD;
      investigator, may benefit from PV-10 administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory</condition>
  <condition>Approved Alternative Therapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PV-10 (10% rose bengal disodium)</intervention_name>
    <description>Intralesional injection for chemoablation of cutaneous or subcutaneous lesions</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older, male or female.&#xD;
&#xD;
          2. Histologically or cytologically confirmed cancer where there is no comparable or&#xD;
             satisfactory approved alternative therapy specific to cutaneous or subcutaneous&#xD;
             tumors.&#xD;
&#xD;
          3. Performance Status: ECOG 0-2.&#xD;
&#xD;
          4. Life Expectancy: At least 6 months.&#xD;
&#xD;
          5. Blood Chemistry:&#xD;
&#xD;
               -  Creatinine ≤ 3 times the upper limit of normal (ULN).&#xD;
&#xD;
               -  Total bilirubin ≤ 3 times the upper limit of normal (ULN).&#xD;
&#xD;
               -  AST/ALT/ALP ≤ 5 times the upper limit of normal (ULN).&#xD;
&#xD;
          6. Thyroid Function&#xD;
&#xD;
               -  Total T3 or free T3 (serum triiodothyronine), total T4 or free T4 (serum&#xD;
                  thyroxine) and THS (serum thyrotropin) ≤ grade 2 abnormality.&#xD;
&#xD;
          7. Renal Function&#xD;
&#xD;
               -  Subjects must have adequate renal function in the opinion of the Investigator&#xD;
                  with no clinically significant renal impairment or uncontrolled renal disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cancer patients who are eligible for an existing PV-10 clinical trial.&#xD;
&#xD;
          2. Certain photosensitizing agents within 5 half-lives prior to PV-10 administration.&#xD;
&#xD;
          3. Concurrent or Intercurrent Illness:&#xD;
&#xD;
               -  Subjects with uncontrolled diabetes or extremity complications due to diabetes.&#xD;
&#xD;
               -  Subjects with severe peripheral vascular disease.&#xD;
&#xD;
               -  Subjects with significant concurrent or intercurrent illness, psychiatric&#xD;
                  disorders, or alcohol or chemical dependence that would, in the opinion of the&#xD;
                  Investigator, compromise their safety or compliance or interfere with&#xD;
                  interpretation of study results.&#xD;
&#xD;
               -  Subjects with uncontrolled thyroid disease, goiter, partial thyroidectomy,&#xD;
                  radioiodine- or surgically-treated Graves' hyperthyroidism or cystic fibrosis.&#xD;
&#xD;
               -  Subjects with clinically significant acute or unstable cardiovascular, (stroke),&#xD;
                  renal, gastrointestinal, pulmonary, immunological (with the exception of the&#xD;
                  presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine,&#xD;
                  or central nervous system disorders.&#xD;
&#xD;
          4. Pregnancy:&#xD;
&#xD;
               -  Female subjects who are pregnant or lactating.&#xD;
&#xD;
               -  Female subjects who have positive serum ßHCG pregnancy test taken within 7 days&#xD;
                  of PV-10 administration.&#xD;
&#xD;
               -  Fertile subjects who are not using effective contraception.&#xD;
&#xD;
          5. Investigational Agents:&#xD;
&#xD;
               -  Subjects who have received investigational agents within 4 weeks (or 5&#xD;
                  half-lives) of study administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>Sydney (North Sydney and Camperdown)</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital Cancer Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

